Bristol Myers Squibb Announces Updated Guidance For BREYANZI Chimeric Antigen Receptor T Cell Therapy Includes Lowered Recommended Duration For Patients To Remain In Close Proximity To Specialized Treatment Centre From 28 Days To 14 Days

Loading news article.

Bristol Myers Squibb Announces Updated Guidance For BREYANZI Chimeric Antigen Receptor T Cell Therapy Includes Lowered Recommended Duration For Patients To Remain In Close Proximity To Specialized Treatment Centre From 28 Days To 14 Days | WAPE

Bristol Myers Squibb Announces Updated Guidance For BREYANZI Chimeric Antigen Receptor T Cell Therapy Includes Lowered Recommended Duration For Patients To Remain In Close Proximity To Specialized Treatment Centre From 28 Days To 14 Days

Article summary

Related companies

Comments —